Table III.
IC50 values of anticancer drugs in control and DAC-resistant HCT116 cells.
| Anticancer drugs | 5-FU (µM) | CPT-11 (µM) | SN-38 (nM) | L-OHP (µM) | Gem (nM) |
|---|---|---|---|---|---|
| Control | 3.34±0.21 | 2.40±0.20 | 2.82±0.14 | 0.71±0.12 | 7.77±0.22 |
| DAC-resistant | 2.79±0.15 | 1.73±0.12 | 1.91±0.28 | 0.64±0.06 | 249.44±8.59 |
| Relative resistance | 0.84 | 0.72 | 0.68 | 0.90 | 32.10 |
| P-value | 0.10 | 0.05a | 0.04a | 0.63 | 9.5×10−6 a |
Values are presented as the mean ± standard error of the mean of three independent experiments. Resistance = IC50(DAC-treated cells)/IC50(control cells).
a
P<0.05 indicates statistical significance. DAC, decitabine; 5-FU, 5-fluorouracil; CPT-11, irinotecan; SN-38, 7-ethyl-10-hydroxycamptothecin; L-OHP, oxaliplatin; Gem, gemcitabine.